Hubbry Logo
Deep hypothermic circulatory arrestDeep hypothermic circulatory arrestMain
Open search
Deep hypothermic circulatory arrest
Community hub
Deep hypothermic circulatory arrest
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Deep hypothermic circulatory arrest
Deep hypothermic circulatory arrest
Deep hypothermic circulatory arrest
View on Wikipedia
from Wikipedia

Deep hypothermic circulatory arrest (DHCA) is a surgical technique in which the temperature of the body falls significantly (between 20 °C (68 °F) to 25 °C (77 °F)) and blood circulation is stopped for up to one hour. It is used when blood circulation to the brain must be stopped because of delicate surgery within the brain, or because of surgery on large blood vessels that lead to or from the brain. DHCA is used to provide a better visual field during surgery due to the cessation of blood flow.[1] DHCA is a form of carefully managed clinical death in which heartbeat and all brain activity cease.

When blood circulation stops at normal body temperature (37 °C), permanent damage occurs in only a few minutes. More damage occurs after circulation is restored. Reducing body temperature extends the time interval that such stoppage can be survived.[2] At a brain temperature of 14 °C, blood circulation can be safely stopped for 30 to 40 minutes.[3] There is an increased incidence of brain injury at times longer than 40 minutes, but sometimes circulatory arrest for up to 60 minutes is used if life-saving surgery requires it.[4][5] Infants tolerate longer periods of DHCA than adults.[6]

Applications of DHCA include repairs of the aortic arch, repairs to head and neck great vessels, repair of large cerebral aneurysms, repair of cerebral arteriovenous malformations, pulmonary thromboendarterectomy, and resection of tumors that have invaded the vena cava.[7][2]

History

[edit]

The use of hypothermia for medical purposes dates back to Hippocrates, who advocated packing snow and ice into wounds to reduce hemorrhage. The origin of hypothermia and neuroprotection was also observed in infants who were exposed to cold due to abandonment and the prolonged viability of these infants.[8]

In the 1940s and 1950s, Canadian surgeon Wilfred Bigelow demonstrated in animal models that the length of time the brain could survive stopped blood circulation could be extended from 3 minutes to 10 minutes by cooling to 30 °C before circulation was stopped.[9] He found that this time could be extended to 15 to 24 minutes at temperatures below 20 °C.[10] He further found that at a temperature of 5 °C, groundhogs could endure two hours of stopped blood circulation without ill effects.[11][12] This research was motivated by a desire to stop the heart from beating long enough to do surgery on the heart while it remained still. Since heart-lung machines, also known as cardiopulmonary bypass (CPB), had not been invented yet, stopping the heart meant stopping blood circulation to the whole body, including the brain.

The first heart surgery using hypothermia to provide a longer time that blood circulation through the whole body could be safely stopped was performed by F. John Lewis and Mansur Taufic at the University of Minnesota in 1952.[13] In this procedure, the first successful open heart surgery, Lewis repaired an atrial septal defect in a 5-year-old girl during 5 minutes of total circulatory arrest at 28 °C. Many similar procedures were performed by Soviet heart surgeon, Eugene Meshalkin, in Novosibirsk during the 1960s.[14] In these procedures, cooling was accomplished externally by applying cold water or melting ice to the surface of the body.

The advent of cardiopulmonary bypass in the United States during the 1950s allowed the heart to be stopped for surgery without having to stop circulation to the rest of the body. Cooling more than a few degrees was no longer needed for heart surgery. Thereafter, the only surgeries that required stopping blood circulation to the whole body ("total circulatory arrest") were surgeries involving blood supply to the brain. The only heart surgeries that continued to require total circulatory arrest were repairs to the aortic arch.

Cardiopulmonary bypass machines were essential to the development of deep hypothermic circulatory arrest (DHCA) in humans.[15] By 1959, it was known from the animal experiments of Bigelow, Andjus and Smith, Gollan, Lewis's colleague, Niazi, and others that temperatures near 0 °C could be survived by mammals,[16][17][18] and that colder temperature permitted the brain to survive longer circulatory arrest times, even beyond one hour.[19] Humans had survived cooling to 9 °C, and circulatory arrest of 45 minutes, using external cooling only.[20] However, reaching such low temperatures by external cooling was difficult and hazardous. At temperatures below 24 °C, the human heart is prone to fibrillation and stopping.[21] This can begin circulatory arrest before the brain has reached a safe temperature. Cardiopulmonary bypass machines allow blood circulation and cooling to continue below the temperature at which the heart stops working. By cooling blood directly, cardiopulmonary bypass also cools people faster than surface cooling, even if the heart is not functioning.

In 1959, using cardiopulmonary bypass (CPB), Barnes Woodhall and colleagues at Duke Medical Center performed the first brain surgery using DHCA, a tumor resection, at a brain temperature of 11 °C and esophageal temperature of 4 °C.[22] This was quickly followed by use of DHCA by Alfred Uihlein and other surgeons for treatment of large cerebral aneurysms, another neurosurgical procedure, for which DHCA is still used today.[23] In 1963, Christiaan Barnard and Velva Schrire were the first to use DHCA to repair an aortic aneurysm, cooling the patient to 10 °C.[13] Randall B. Griepp, in 1975, is generally credited with demonstrating DHCA as a safe and practical approach for aortic arch surgery.[24][13]

Mechanism of brain protection

[edit]

Cells require energy to operate membrane ion pumps and other mechanisms of cellular homeostasis. Cold reduces the metabolic rate of cells, which conserves energy stores (ATP) and oxygen needed to produce energy. Cold therefore extends the length of time that cells can maintain homeostasis and avoid damaging hypoxia and anaerobic glycolysis by conserving local resources when blood circulation is stopped and unable to deliver fresh oxygen and glucose to make more energy.[25]

Normally 60% of brain oxygen utilization (CMRO2) consists of energy generation for the neuronal action potentials of brain electrical activity.[26]

A key principle of DHCA is total inactivation of the brain by cooling, as verified by "flatline" isoelectric EEG, also called electrocerebral silence (ECS). Instead of a continuous decrease in activity as the brain is cooled, electrical activity decreases in discontinuous steps. In the human brain, a type of reduced activity called burst suppression occurs at a mean temperature of 24 °C, and electrocerebral silence occurs at a mean temperature of 18 °C.[27] The achievement of measured electrocerebral silence has been called "a safe and reliable guide" for determining cooling required for individual patients,[28] and verification of electrocerebral silence is required prior to stopping blood circulation to begin a DHCA procedure.[29]

Secondary to conservation of local energy resources by metabolic slowing and brain inactivation, hypothermia also protects the brain from injury by other mechanisms during stopped blood circulation. These include reduction of free radicals and immune-inflammatory processes.[25]

Temperatures used

[edit]

Mild hypothermia (32 °C to 34 °C) and moderate hypothermia (26 °C to  31 °C)[30] are contraindicated for hypothermic circulatory arrest because 100% and 75% of people respectively will not achieve electrocerebral silence in these temperature ranges.[31] Consequently, safe circulatory arrest times for mild and moderate hypothermia are only 10 and 20 minutes respectively.[32] While moderate hypothermia may be satisfactory for short surgeries, deep hypothermia (20 °C to 25 °C) affords protection for times of 30 to 40 minutes at the bottom of this temperature range.

Profound hypothermia (< 14 °C) usually isn't used clinically. It is a subject of research in animals and human clinical trials. As of 2012, the lowest body temperature ever survived by a human being was 9 °C (48 °F) as part of a hypothermic circulatory arrest experiment to treat cancer in 1957.[33][34] This temperature was reached without surgery, using external cooling alone. Similar low temperatures are expected to be reached in emergency preservation and resuscitation (EPR) clinical trials described in the Research section of this article.

Cooling techniques

[edit]

Since the benefits of hypothermia were discovered there have been numerous methods used to cool the body to desired temperatures. Hippocrates used snow and ice to surface cool wounded patients to prevent excessive bleeding.[8] This method would fall under conventional cooling techniques, in which cold saline and crushed ice are used to induce a state of hypothermia to the patient. These techniques are inexpensive but lack the precision needed to maintain target temperatures and require careful monitoring.[35] It has been proven to help prevent undesirable rewarming of the brain during DHCA.[30] Hospitals and emergency medical services commonly use surface cooling systems that circulate cold air or water around blankets or pads. Advantages of this method are accuracy of cooling due to auto-regulating temperature control, feedback probes, applicable in non-hospital settings, and non-complexity of use.[8] Drawbacks to surface cooling systems is skin irritation, shivering and rate of cooling.[36] Intravascular cooling systems regulate temperature from inside veins such as the femoral, sub-clavian, or internal jugular to reduce adverse effects that external cooling methods cause. This method is unparalleled in achieving and maintaining the target temperature desired.[8] The use of continuous renal replacement therapy (CRRT) has proven effective in the induction of hypothermia as an intravascular cooling system.[8]

Method

[edit]

People who are to undergo DHCA surgery are placed on cardiopulmonary bypass (CPB), a procedure that uses an external heart-lung machine that can artificially replace the function of the heart and lungs.[37] A portion of the circulating blood supply is removed and stored for later replacement, with the remaining blood diluted by added fluids with the objective of reducing viscosity and clotting tendencies at cold temperature.[38][39] The remaining diluted blood is cooled by the heart-lung machine until hypothermia causes the heart to stop beating normally, after which the blood pump of the heart-lung machine continues blood circulation through the body. Corticosteroids are typically given 6–8 hours before surgery as it has shown to have neuroprotective properties to decrease risk of neurological dysfunction by decreasing the release of inflammatory cytokines.[2] Glucose is eliminated from all intravenous solutions to reduce the risk of hyperglycemia.[30] In order for accurate hemodynamic monitoring, arterial monitoring is typically placed in the femoral or radial artery.[2] Temperature taken from two separate sites, typically the bladder and nasopharynx, is used to estimate brain and body temperatures.[2] Cardioplegic drugs may be administered to ensure the heart stops beating completely (asystole), which is protective of both the heart and brain when circulation is later stopped.[40] Cooling continues until the brain is inactivated by the cold, and electrocerebral silence (flatline EEG) is attained. The blood pump is then switched off, and the interval of circulatory arrest begins. At this time more blood is drained to reduce residual blood pressure if surgery on a cerebral aneurysm is to be performed to help create a bloodless surgical field.[41]

After surgery is completed during the period of cold circulatory arrest, these steps are reversed. The brain and heart naturally resume activity as warming proceeds. The first activity of the warming heart is sometimes ventricular fibrillation requiring cardioversion to re-establish a normal beating rhythm.[42] Except for the period of complete inactivation just prior to and during the circulatory arrest interval, barbiturate infusion is used to keep the brain in a state of burst suppression for the entirety of the DHCA procedure until emergence from anesthesia.[43] Hypothermic perfusion is maintained for 10–20 minutes while on CPB before rewarming as to reduce the risk of increased intracranial pressure.[2] Warming must be done carefully to avoid overshooting normal body temperature. It is recommended that rewarming is stopped once the body is warmed to 37 °C.[30] Post-operative hyperthermia is associated with adverse outcomes.[44] Patients are completely rewarmed before discontinuing CPB, but temperature remain labile despite rewarming efforts which requires close monitoring in the ICU.[2]

Complications

[edit]

The use of hypothermia following cardiac arrest shows increased likelihood of survival. It is the re-warming period that, if not controlled properly, can have detrimental effects. Hyperthermia during the re-warming period shows unfavorable neurologic outcomes. For each degree the body is warmed above 37 °C, there is an increased association with severe disability, coma, or vegetative states.[8] Excessive rewarming with temperatures above 37 °C can increase the risk of cerebral ischemia secondary to the increased oxygen demand that occurs with rapid rewarming.[2] Several theories have been proposed, with one being during re-warming, the body releases increasing catecholamines which increase heat production leading to a loss of thermoregulation.[8] Hyperthermia in the preperfusion period can also be caused by an increase in the production of oxygen radicals, which influences brain metabolism.[8] These oxygen radicals attack cell membranes, leading to a disruption of intracellular organelles and subsequent cellular death.[30]

Virtually all patients who undergo DHCA develop impaired glucose metabolism and require insulin to control blood sugars.[2] Thrombocytopenia and clotting factor deficiencies prove to be a significant cause of early death after DHCA. Careful monitoring intra-procedure and post-procedure is needed.[2]

Although DHCA is necessary for some procedures, the use of anesthesia can provide optimum operation time and organ protection but can also have serious impacts on cellular demand, brain cells, and serious systemic inflammatory results.[45] Possible disadvantages of DHCA includes alteration in organ functions of the liver, kidney, brain, pancreas, intestines and smooth muscles due to cellular damage. Permanent neurological injury has been seen in 3-12% of patients when using DHCA.[30] Cases of partial or complete limb motor loss, impaired language, visual defects, and cognitive decline have all been reported as consequences of DHCA.[45] Other neurological complications include increased risk for seizures postoperative due to delayed return of cellular blood flow to the brain.[1] When compared to Moderate Hypothermia (temperature dropped to 26-31 °C[30]), there was less bleeding volume experienced during surgery thus leading to less use of packed red blood cells or plasma post surgery.[45] Longer recovery time postoperatively have been noted with DHCA as compared to Moderate Hypothermia, but the length of hospital stay and death has no correlated difference.[45] Most patients can tolerate 30 minutes of DHCA without significant neurological dysfunction or adverse effects, but after an extended period of 40 minutes or more, prevalence of increased brain injury have been noted.[2]

Research

[edit]

One of the anticipated medical uses of long circulatory arrest times, or so-called clinical suspended animation, is treatment of traumatic injury. In 1984 CPR pioneer Peter Safar and U.S. Army surgeon Ronald Bellamy proposed suspended animation by hypothermic circulatory arrest as a way of saving people who had exsanguinated from traumatic injuries to the trunk of the body.[46] Exsanguination is blood loss severe enough to cause death. Until the 1980s, it had been thought impossible to resuscitate people whose heart stopped because of blood loss, resulting in these people being declared dead when cardiac resuscitation failed. Traditional treatments such as CPR and fluid replacement or blood transfusion are not effective when cardiac arrest has already occurred and bleeding remains uncontrolled.[47] Safar and Bellamy proposed flushing cold solution through blood vessels of patients with deadly bleeding, and leaving them in a state of cold circulatory arrest with the heart stopped until the cause of bleeding could be surgically repaired to allow later resuscitation. In preclinical studies at the University of Pittsburgh during the 1990s, the process was called deep hypothermia for preservation and resuscitation, and then suspended animation for delayed resuscitation.[48]

The process of cooling people with fatal bleeding for surgical repair and later resuscitation was finally called Emergency Preservation and Resuscitation for Cardiac Arrest from Trauma (EPR-CAT), or EPR.[49][50][51][52] It is presently undergoing human clinical trials.[53] In the trials, patients who experience clinical death for less than five minutes duration from blood loss are being cooled from normal body temperature of 37 °C to less than 10 °C by pumping a large quantity of ice-cold saline into the largest blood vessel of the body (aorta). By remaining in circulatory arrest at temperatures below 10 °C (50 °F), it is believed that surgeons have one[54] to two hours[55][56] to fix injuries before circulation must be restarted. Surgeons involved with this research have said that EPR changes the definition of death for victims of this type of trauma.[57]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Deep hypothermic circulatory arrest

View on Grokipedia
from Grokipedia
Deep hypothermic circulatory arrest (DHCA) is a surgical technique that induces profound , typically cooling the body to 18–20°C, and temporarily halts to stop blood circulation, thereby reducing metabolic demands and providing during complex operations such as aortic arch repairs. This method allows surgeons a bloodless operative field for up to 30–40 minutes while minimizing ischemic injury to the and other organs by slowing cellular by approximately 6–7% for each 1°C decrease below normothermia. The technique originated in the early when first applied surface cooling and brief circulatory arrest for open-heart procedures, such as closure, before the widespread adoption of . Advancements in the and 1960s integrated pump-oxygenators and heat exchangers, enabling more controlled core cooling, with significant refinement for surgery occurring in the 1970s under pioneers like Randall Griepp. Today, DHCA remains a cornerstone for surgeries requiring uninterrupted access to the , including repairs, dissections, and pulmonary thromboendarterectomies for . During the procedure, patients under general anesthesia are connected to a machine, which circulates cooled blood to achieve the target , often with the head packed in for additional cerebral cooling; circulation is then arrested, and the body is rewarmed gradually over about 60 minutes post-repair to avoid complications like . arises from hypothermia's ability to suppress cerebral electrical activity—at temperatures around 12.7°C, electrocerebral silence occurs in 95% of patients—and to inhibit excitotoxic pathways, such as glutamate release and calcium influx, while limiting anaerobic metabolism and lactate buildup. Despite its efficacy, DHCA carries risks including , arrhythmias, and neurological deficits, with rates averaging 3.1% in large series but rising to 13.1% when exceeds 45 minutes, often due to embolic rather than purely ischemic events. A study of 394 patients reported a mean time of 31 minutes (range 10–66 minutes), overall mortality of 2.2%, and no significant long-term cognitive decline, underscoring DHCA's safety when limited in duration. Adjunctive strategies, such as selective antegrade cerebral perfusion or pharmacologic agents like corticosteroids, are sometimes employed to extend safe times, though evidence for their superiority remains mixed.

Overview

Definition and Principles

Deep hypothermic circulatory arrest (DHCA) is a surgical technique employed during complex cardiovascular procedures, particularly those involving the , wherein the patient's core body temperature is systemically reduced to 18–20°C through , followed by the temporary cessation of circulation for up to 30–40 minutes to create a bloodless operative field. This method allows surgeons to perform intricate repairs without the constraints of ongoing blood flow, while minimizing ischemic injury to vital organs. The core principles of DHCA revolve around profound metabolic suppression to protect organs, especially the , during the period of global ischemia. By cooling the body to deep hypothermic levels, the cerebral metabolic rate for oxygen decreases to approximately 12–25% of normothermic baseline values, thereby drastically reducing oxygen demand and preventing the onset of anaerobic metabolism. Achievement of electrocerebral silence, confirmed via , further indicates maximal , as this state signifies near-complete halt of electrical activity and associated metabolic processes. The physiological rationale underlying DHCA stems from hypothermia's ability to diminish cerebral blood flow and in parallel, maintaining a critical balance that averts cellular damage from oxygen deprivation. As temperature drops, enzymatic activities slow, inhibiting pathways that lead to , , and during ischemia; this is particularly vital for the , where even brief interruptions in can cause irreversible harm under normothermic conditions. The reduction in metabolic rate with hypothermia is quantitatively approximated using the Q_{10} temperature coefficient, which typically ranges from 2 to 2.5 for cerebral metabolism, indicating that the rate halves for every 10°C decrease in temperature. This coefficient derives from the van't Hoff rule, originally formulated for the temperature dependence of chemical reaction rates in solutions, where reaction velocity often doubles with a 10°C rise (Q_{10} = 2), and has been adapted to poikilothermic biological systems to model metabolic changes. The metabolic rate MM at temperature TT relative to a baseline M0M_0 at T0T_0 (e.g., 37°C) is given by: M(T)=M0×Q10T−T010M(T) = M_0 \times Q_{10}^{\frac{T - T_0}{10}} For DHCA at approximately 18°C, with Q10=2.3Q_{10} = 2.3 and ΔT=−19°C\Delta T = -19°C, the exponent yields 2.3−1.9≈0.172.3^{-1.9} \approx 0.17, reducing the rate to about 17% of baseline, thereby extending safe ischemic tolerance.

Historical Development

The conceptual origins of deep hypothermic circulatory arrest (DHCA) trace back to ancient observations on the preservative effects of extreme cold. In the 4th century BCE, Hippocrates and scholars of the Hippocratic School in Ancient Greece documented how profound cold could induce a state of suspended animation in living organisms, temporarily halting vital processes while preserving life, laying an early groundwork for therapeutic hypothermia. These insights, though rudimentary, highlighted cold's potential to mitigate metabolic demands during physiological stress. In the early , modern experimentation began with animal studies on hypothermia's neuroprotective benefits. During , neurosurgeon Temple Fay conducted pioneering work, cooling animals and later humans to temperatures as low as 28°C to reduce metabolism during tumor resections, demonstrating hypothermia's role in extending safe periods of reduced flow. Fay's 1938-1940 human trials marked a shift toward controlled clinical application, influencing subsequent cardiac by showing that lowering body could protect organs from ischemia. The first human uses of DHCA emerged in the 1950s amid advances in . On September 2, 1952, F. John Lewis performed the inaugural successful open-heart procedure, closing an in a 5-year-old girl using surface-induced to 28°C followed by brief circulatory arrest, without . In 1953, John H. Gibbon Jr. introduced the heart-lung machine for extracorporeal circulation, enabling safer integration of deep with circulatory arrest for more complex intracardiac repairs. These milestones transformed DHCA from experimental to viable for pediatric and adult cardiac interventions. By the 1970s and , DHCA gained routine adoption for surgery, driven by key surgical innovators. In , Randall B. Griepp reported the first series of four repairs using DHCA at 18-20°C via combined surface and core cooling with , achieving operative success and establishing the technique's practicality for extensive aortic reconstruction. E. Stanley Crawford further advanced its use in the for thoracoabdominal aneurysms, refining approaches in large clinical series that confirmed DHCA's efficacy in providing a bloodless field for complex repairs. Early clinical outcomes from these eras, including Griepp's and Crawford's cohorts, defined safe arrest durations of 30-45 minutes at nasopharyngeal temperatures of 18°C, based on low rates of neurological deficits in over 100 cases, guiding limits to minimize ischemic risks. In the , DHCA underwent standardization through accumulated evidence and professional society recommendations. Clinical series from major centers, such as those involving over 1,000 aortic procedures, solidified protocols for temperature thresholds (typically 16-20°C) and arrest times under 40 minutes to optimize cerebral protection, with societies like the Society of Thoracic Surgeons incorporating these into broader guidelines on hypothermic management during . This era's refinements, emphasizing pH-stat blood gas management and multimodality monitoring, cemented DHCA as a cornerstone for high-risk thoracic aortic operations.

Indications

Surgical Applications

Deep hypothermic circulatory arrest (DHCA) is primarily indicated for complex aortic surgeries requiring a bloodless field, such as repair of aneurysms, where it facilitates safe manipulation of the arch vessels without ongoing . In emergent cases of acute Stanford type A , DHCA enables rapid reconstruction of the dissected arch while minimizing ischemic risks to distal organs. For neonatal cardiac procedures, DHCA is essential in repairs for , particularly during the Norwood stage, allowing precise reconstruction of the hypoplastic arch and systemic outflow. Beyond these core indications, DHCA finds application in neurosurgical interventions like clipping of complex cerebral aneurysms, where temporary cessation of circulation provides during intricate vessel isolation. It is also utilized in for , enabling complete removal of organized thrombi from the pulmonary vasculature under a still field. In select adult congenital heart surgeries, such as reoperations for residual defects or complex transpositions, DHCA supports procedures involving the great vessels when standard is insufficient. The safe duration of circulatory arrest varies by patient age, with adults generally tolerating 20-40 minutes before risks of neurological injury escalate, reflecting metabolic suppression at core temperatures of 18-20°C. Infants and neonates exhibit greater tolerance, often up to 45 minutes, attributable to their higher baseline metabolic flexibility and more efficient cerebral cooling. In total arch replacement, DHCA plays a pivotal role by allowing en bloc resection and grafting of the entire arch, often combined with antegrade cerebral perfusion for extended cases exceeding standard arrest limits. Similarly, in elephant trunk procedures for extensive aneurysmal disease, DHCA facilitates deployment of the proximal graft trunk into the , bridging staged repairs while protecting end-organ function during the arrest phase. DHCA is also applied in the repair of descending thoracic and thoracoabdominal aortic aneurysms, particularly in open surgical techniques requiring circulatory for distal control.

Patient Selection

Patient selection for deep hypothermic circulatory arrest (DHCA) prioritizes individuals who can tolerate the physiological stresses of profound and circulatory cessation, typically those undergoing complex repairs or congenital heart surgeries where alternative strategies are insufficient. Ideal candidates include neonates and infants requiring intricate repairs for congenital anomalies, such as or interrupted , due to their greater metabolic plasticity and shorter expected arrest times. Risk factors play a critical role in determining suitability, with advanced age serving as a relative owing to reduced tolerance for ischemia and higher incidence during DHCA. Preexisting neurological conditions, such as prior or , increase vulnerability to brain injury, while renal impairment and coagulopathies heighten the likelihood of systemic complications like or bleeding post-rewarming. Elderly patients and those with significant in the are often selected cautiously, favoring adjunctive cerebral if arrest duration may exceed 30 minutes. Preoperative evaluation is essential to assess tolerance and optimize outcomes, beginning with advanced imaging such as computed tomography (CT) angiography or (MRI) to delineate arch pathology and guide cannulation sites. Neurological baseline assessment, including (EEG) to establish pre-arrest brain activity patterns, aids in postoperative comparison for detecting deficits. Hematologic workup, encompassing profiles and renal function tests, identifies potential or impairment that could contraindicate DHCA. Stratification tools like the EuroSCORE II are adapted for DHCA cases to quantify operative mortality risk, incorporating variables such as age, renal function, and extracardiac arteriopathy to weigh benefits against neurological and systemic hazards. This scoring system helps classify patients into low-, intermediate-, or high-risk categories, informing decisions on whether DHCA alone suffices or requires adjuncts like selective antegrade cerebral . In thoracic aortic cohorts, EuroSCORE II has demonstrated reliability in predicting outcomes, with higher scores correlating to elevated morbidity.

Physiological Mechanisms

Neuroprotection

Deep hypothermic circulatory arrest (DHCA) provides primarily by decreasing cerebral , which reduces the brain's oxygen and energy demands during periods of ischemia. This metabolic suppression occurs at a rate of approximately 5-7% per degree drop in temperature, reaching 12-25% of normothermic levels at 18°C, thereby extending the safe duration of circulatory arrest. At the cellular level, hypothermia mitigates excitotoxicity by inhibiting glutamate release and reducing glycine-mediated activation of NMDA receptors, which limits calcium influx and subsequent neuronal damage. Additionally, DHCA preserves ATP levels by slowing its breakdown more than synthesis, supporting cellular during ischemia. Anti-apoptotic effects are achieved through inhibition of pathways, reducing in vulnerable neurons. Hypothermia further stabilizes neuronal membranes by lowering free release, which prevents structural disruption, while also decreasing production of and free radicals that exacerbate ischemic injury. is curtailed through suppression of pro-inflammatory cytokines, minimizing post-ischemic and secondary damage. A key marker of maximal is electroencephalographic (EEG) silence, achieved at nasopharyngeal temperatures typically between 12-18°C, with electrocerebral silence occurring in 95% of patients around 12.7°C; achievement varies, with approximately 60% of patients reaching it by 18°C, indicating profound metabolic quiescence and alignment of protective pathways such as inhibition. Adjunctive management of blood gases during cooling influences ; alpha-stat strategy maintains pH at 7.40 uncorrected for , promoting metabolic suppression and reducing microembolic risks, whereas pH-stat adjusts to 7.40 at the patient's , enhancing cerebral blood flow and alkalinity to support deeper cooling.

Temperature Effects

Deep hypothermic circulatory arrest (DHCA) employs profound systemic cooling to temperatures typically ranging from 18°C to 20°C, achieving significant metabolic suppression that extends the safe duration of circulatory arrest. This range allows for a reduction in oxygen demand to approximately 12-25% (75-88% reduction) compared to normothermic conditions, enabling brief periods of global ischemia during complex aortic surgeries. Moderate , targeted at 25°C to 28°C, is increasingly considered as an alternative strategy, offering a balance between metabolic protection and reduced risk of hypothermia-related complications. At these low temperatures, hypothermia exerts multifaceted systemic effects on organ function. Cardiac risks include a heightened propensity for arrhythmias, particularly , when core temperatures fall below 20°C, due to altered myocardial kinetics and slowed conduction. Renal effects involve pronounced of the , which can precipitate (AKI) through reduced glomerular filtration and ischemic insult, with incidence rates up to 40% in DHCA procedures. Hematologic changes are characterized by increased blood viscosity from hemoconcentration and cold-induced rigidity, exacerbating microvascular resistance and potentially contributing to during rewarming. The physiological basis for these protective yet challenging effects lies in the exponential reduction of metabolic rate with decreasing temperature, modeled by the Q10 temperature coefficient. Oxygen consumption (VO2) decreases according to the equation: VO2=VO2norm×Q10(Tnorm−T)10\text{VO}_2 = \text{VO}_{2\text{norm}} \times Q_{10}^{\frac{(T_{\text{norm}} - T)}{10}} where VO2norm is the baseline oxygen consumption at normal body temperature (Tnorm = 37°C), T is the hypothermic temperature, and Q10 ≈ 2.3 for human metabolic processes, reflecting an approximate doubling of metabolic rate for every 10°C increase. This derivation stems from an exponential decay model of enzymatic activity and cellular respiration, validated in hypothermic surgical contexts where whole-body oxygen demand falls sharply below 25°C. Organ tolerance to ischemia during DHCA varies by tissue resilience, with safe circulatory arrest durations generally limited to 30-40 minutes at 18-20°C to minimize irreversible damage across systems. The liver demonstrates greater tolerance to ischemia than the in hypothermic conditions due to its high stores and regenerative capacity, though clinical applications prioritize shorter intervals for multi-organ safety.

Procedure

Cooling Techniques

Deep hypothermic circulatory arrest (DHCA) primarily relies on core cooling methods to achieve profound systemic , typically targeting nasopharyngeal temperatures of 15–20°C for during aortic arch surgery. The cornerstone technique involves (CPB) using a to circulate cooled, oxygenated blood through the patient's vascular system, enabling controlled and efficient reduction of core body temperature. This method allows for a uniform drop in temperature across vital organs, with cooling phases lasting 30–40 minutes to reach the target from normothermia. Surface cooling serves as an adjunct to core methods, particularly to accelerate peripheral and cranial , though it is less efficient when used alone due to slower . Common approaches include applying packs to the head and torso, as well as using cooling blankets or circulating water pads to promote convective heat loss from the skin. These techniques are often employed concurrently with CPB to minimize temperature gradients and enhance overall cooling homogeneity, with head icing specifically aimed at reducing temperature more rapidly despite limitations from insulation. Precise temperature monitoring is essential during cooling to ensure safe progression and avoid uneven hypothermia. Probes are typically placed in the nasopharynx (7–10 cm depth, approximating brain temperature) and urinary bladder (reflecting core temperature), with a target gradient of less than 10°C maintained between peripheral and central sites to prevent . This monitoring guides adjustments in CPB flow and settings, ensuring the process remains within physiological tolerances. Cooling protocols emphasize gradual implementation to mitigate risks such as , arrhythmias, or gaseous emboli, with a recommended rate of 0.5–1°C per minute achieved via adjusted CPB pump speeds and exchanger temperatures. Acid-base strategies, such as alpha-stat (maintaining at 7.40 and PaCO₂ at 40 mmHg uncorrected for temperature) or pH-stat (correcting to 7.40 at patient temperature), are employed to optimize cerebral blood flow and oxygenation; alpha-stat is generally preferred in adults for preserving autoregulation, while pH-stat may be used during the cooling phase for enhanced homogeneity. These protocols are tailored based on patient age and surgical duration, drawing from guidelines by organizations like the Society of Thoracic Surgeons.

Operative Method

The operative method of deep hypothermic circulatory arrest (DHCA) commences with cannulation to establish (CPB). Arterial cannulation is preferentially performed through the right using a prosthetic graft to minimize vessel wall injury, or alternatively via the if axillary access is contraindicated due to ; venous cannulation occurs through the right atrial appendage with a two-stage or the . Once CPB is initiated, the cooling phase begins, gradually reducing the patient's core temperature to 18–20°C over 20–40 minutes while maintaining a of less than 10°C between the arterial outflow and venous return to prevent uneven heating or cooling. Prior to inducing arrest, electroencephalographic (EEG) silence is verified to confirm profound cerebral hypothermia and metabolic suppression, typically achieved at nasopharyngeal temperatures between 14.1°C and 20°C. Circulatory arrest is then initiated by clamping the CPB circuit and draining residual blood into the oxygenator reservoir, with a timer started to track the arrest duration; safe limits are generally 20–30 minutes without adjunctive perfusion, extending to under 40 minutes in total for most adult patients, adjusted based on age, comorbidities, and procedural complexity to minimize ischemic risk. During this period, the ascending aorta is cross-clamped to isolate the operative field, and cold cardioplegia solution is administered antegrade or retrograde to provide myocardial protection and arrest the heart, ensuring a still and bloodless environment for surgical intervention such as aortic arch reconstruction. Following completion of the surgical repair, rewarming is instituted on resumed CPB, advancing the core temperature gradually at a rate of approximately 0.3°C per minute to normothermia (36–37°C), with the total process spanning about while strictly limiting the perfusate-to-patient temperature gradient to under 10°C initially and less than 4°C near completion to avoid gas emboli, protein denaturation, or rebound . Core temperatures are not permitted to exceed 37°C at the oxygenator outlet, and monitoring via or esophageal probes ensures uniform rewarming.

Complications

Neurological Risks

Deep hypothermic circulatory arrest (DHCA) carries significant neurological risks, primarily manifesting as , transient neurological dysfunction (TND), and permanent deficits. Stroke occurs in 2-13% of cases, often due to embolic events or hypoperfusion during the procedure, while TND, characterized by reversible deficits such as or focal weakness, affects 5-20% of patients and typically resolves within days. Permanent neurological injuries, including or motor deficits, arise from mechanisms like emboli dislodgement or inadequate cerebral protection, with meta-analyses reporting rates of about 4-9% for such lasting damage. The of these complications stems from incomplete despite 's metabolic suppression, leading to ischemia-reperfusion injury upon rewarming, where and exacerbate neuronal damage. Watershed infarcts, occurring in border-zone areas vulnerable to hypoperfusion, are common in prolonged arrests, while induced by profound can precipitate through platelet dysfunction and fibrinolytic activation. Embolic strokes may result from atherosclerotic debris mobilized during aortic manipulation, independent of arrest duration in some cases. Key risk factors include circulatory arrest durations exceeding 45 minutes, which correlate with heightened incidence of both TND and permanent deficits due to cumulative ischemic burden, and profound below 18°C, which amplifies and reperfusion risks. Patient-specific factors such as advanced in the increase embolic potential, with odds ratios for rising significantly in affected individuals. Preoperative conditions like or chronic renal failure further elevate vulnerability by impairing . Postoperative assessment relies on clinical neurologic examinations, with MRI preferred for detecting early infarcts or white matter changes and EEG for identifying subclinical seizures, which occur more frequently after extended DHCA and signal potential injury. Meta-analyses confirm these tools' utility in quantifying incidence, such as the 4-9% permanent injury rate, aiding timely intervention to mitigate long-term sequelae.

Systemic Complications

Deep hypothermic circulatory arrest (DHCA) is associated with significant hematologic complications, primarily resulting from hypothermia-induced platelet dysfunction, enzymatic inhibition in the coagulation cascade, and hemodilution during prolonged (CPB). This leads to increased bleeding risk, with transfusion requirements occurring in approximately 40-60% of cases during surgery. Management typically involves prophylactic administration of antifibrinolytic agents such as or epsilon-aminocaproic acid to stabilize clots and reduce perioperative blood loss. Renal complications, including (AKI), arise from hypothermic , reduced renal during CPB, and inflammatory responses upon rewarming, with an incidence of 15-50% in patients undergoing DHCA for aortic procedures. AKI often manifests as elevated levels requiring monitoring and supportive care, though is needed in only 2-5% of cases. Pulmonary issues, such as prolonged , stem from rewarming-induced systemic inflammation and after extended CPB times, affecting up to 25% of patients and extending intensive care stays. Metabolic disturbances during DHCA include due to impaired insulin sensitivity and stress hormone release, alongside shifts such as and from hemodilution and . Rewarming can precipitate , exacerbating and potentially leading to multi-organ dysfunction if core temperatures exceed 37.5°C. These are managed through insulin infusion for glycemic control and replacement guided by serial monitoring. Overall, systemic complications contribute to an in-hospital of 5-10% in adult DHCA patients, primarily from multi-organ failure or hemorrhage, while pediatric outcomes show lower mortality around 6-7% due to smaller body size and shorter arrest times. Long-term recovery is generally favorable with supportive care, though subtle systemic effects may influence in survivors.

Alternatives

Moderate Hypothermia

Moderate hypothermic circulatory arrest (MHCA) is defined as the induction of circulatory arrest during at core body temperatures ranging from 25°C to 28°C, a range that facilitates shorter cooling and rewarming phases on compared to deeper protocols. This temperature threshold reduces the overall duration of , typically by 60-80 minutes, thereby minimizing exposure to bypass-related stressors. Additionally, MHCA at these levels attenuates -induced by preserving platelet function and enzymatic factors better than colder temperatures, leading to lower perioperative blood loss and transfusion requirements. Key advantages of MHCA include a decreased incidence of cardiac arrhythmias, such as , due to less profound metabolic suppression and shifts associated with milder cooling, as well as accelerated postoperative recovery from reduced bypass times and lower inflammatory responses. These benefits are evidenced by a 2023 multicenter randomized involving patients undergoing surgery, which demonstrated that low-moderate (20.1-28°C) was noninferior to deep hypothermia (<20.1°C) in terms of neurological outcomes, with comparable 30-day mortality and rates but shorter operative times. In terms of protocol, MHCA limits safe circulatory arrest duration to approximately 20-30 minutes without adjunctive cerebral , shorter than the 40-45 minutes tolerated in deep hypothermia, to prevent ischemic injury from reduced oxygen solubility at higher temperatures. To extend operative windows when needed, MHCA is sometimes integrated with brief intermittent pauses, allowing targeted organ reperfusion while maintaining overall hypothermic protection. Supporting evidence from recent meta-analyses highlights MHCA's superiority in mitigating systemic complications; for instance, a 2020 reported an of 0.76 (approximately 24% relative reduction) in renal failure and decreased need for compared to deep hypothermic circulatory arrest, attributed to diminished inflammatory cascades and faster metabolic recovery. These findings underscore MHCA's role as a viable alternative for select arch procedures, balancing efficacy with procedural efficiency.

Cerebral Perfusion Strategies

Cerebral perfusion strategies are adjunctive techniques employed during deep hypothermic circulatory arrest (DHCA) to deliver targeted blood flow to the , thereby extending the safe duration of systemic circulatory arrest and reducing ischemic risks in aortic arch surgery. These methods, including selective antegrade cerebral perfusion (SACP) and retrograde cerebral perfusion (RCP), maintain cerebral oxygenation and metabolic support while the remainder of the body is under arrest, allowing for more complex repairs without excessive neurological compromise. Selective antegrade cerebral (SACP) involves cannulation of the right axillary or to provide direct, physiologic antegrade flow exclusively to the cerebral vasculature during the arrest phase. This unilateral or bilateral approach ensures brain-only , with typical flow rates of 10-15 mL/kg/min adjusted based on monitoring to maintain adequate cerebral . SACP is particularly valued for its ability to mimic normal hemodynamics, minimizing emboli risk through controlled delivery. Retrograde cerebral perfusion (RCP), in contrast, delivers oxygenated blood via the at flow rates of 300-500 mL/min, promoting backfilling of the cerebral venous system to facilitate cooling and limited nutrient delivery during arrest. This technique requires careful pressure management (typically 20-25 mmHg) to avoid venous engorgement and is simpler to implement without arterial cannulation in the arch. Both SACP and RCP extend the safe DHCA duration to over 90 minutes in select cases, surpassing the 40-50 minute limit of straight DHCA alone by providing ongoing cerebral protection. In neonatal reconstruction, studies including a 2024 analysis report low overall rates of neurological events regardless of strategy, with some cohorts showing 0% events in DHCA groups and non-significant differences when SACP is added, though earlier research suggests potential benefits of in reducing incidence and severity. Comparative analyses favor SACP in adult patients for its precision and superior reduction in temporary neurological dysfunction, achieving lower transient deficits than RCP while maintaining similar rates of permanent injury or . RCP remains a viable, simpler option in complex arch anatomies where antegrade access is challenging, though it is generally less effective due to non-nutritive flow patterns.

Research

Recent Advancements

In recent years, has focused on optimizing hypothermic circulatory arrest (HCA) strategies to balance with reduced procedural risks in surgery. The GOT-ICE trial, a multicenter randomized controlled study published in 2023, compared low-moderate (20.1–24.0°C) with traditional deep (≤20.0°C) during HCA with antegrade cerebral . The trial enrolled 286 patients undergoing elective surgery and found that low-moderate hypothermia was noninferior to deep hypothermia in preserving global cognitive function, with no significant differences in composite neurologic outcomes or mortality at 30 days (2.8% vs. 3.5%, P=0.78). Additionally, the low-moderate group experienced less , evidenced by reduced transfusions and shorter activated clotting times, supporting its adoption to mitigate bleeding complications associated with profound cooling. A 2025 meta-analysis of 6 studies (4 RCTs, 2 observational) involving 381 patients undergoing surgery found moderate with selective antegrade cerebral (SACP) associated with higher perioperative risk compared to deep hypothermic circulatory arrest (DHCA) alone (RR 1.74, 95% CI 1.30–2.35). It suggests moderate with SACP as a viable alternative but emphasizes the need for further studies to reduce practice variability. Technological innovations in (CPB) systems have also refined DHCA implementation. Advanced CPB machines with automated temperature management enable precise control, reducing variability in temperature during procedures. In pediatric surgery, a 2024 published in the Journal of Thoracic and Cardiovascular Surgery Open compared DHCA without to SACP in 165 neonates and infants (51 DHCA, 114 SACP) undergoing Norwood or similar procedures. The study reported rates of 98% for DHCA vs. 91% for SACP (P=0.17), with no significant differences in neurologic events (0% vs. 3.5%, P=0.31, limited by small event numbers) or length of stay. DHCA proved particularly advantageous in low-resource settings due to procedural simplicity, while SACP offered flexibility for extended arch reconstructions; these findings support DHCA as a viable option in infants when combined with vigilant monitoring.

Emerging Applications

One promising emerging application of deep hypothermic circulatory arrest (DHCA) lies in trauma , particularly through the Emergency Preservation and (EPR) approach for patients experiencing due to hemorrhagic shock. The ongoing EPR (NCT01042015), initiated to test the feasibility and safety of inducing profound below 10°C via rapid of ice-cold saline to suspend animation and allow surgical , remains in recruiting status as of November 2025, with preclinical studies demonstrating survival rates up to 86% in animal models of exsanguination followed by delayed . In post-cardiac arrest care, principles derived from DHCA are informing investigational strategies for , such as personalized temperature targets tailored to severity in out-of-hospital arrests. A 2025 study in JACC Advances advocates a neurologically driven protocol, recommending deeper (32–34°C) for severe cases with malignant EEG patterns or low scores, building on evidence from trials like HACA showing improved neurological outcomes with cooling to 32–34°C compared to normothermia (55% vs. 39% favorable outcomes). While not directly employing circulatory arrest, this personalization echoes DHCA's metabolic suppression for protection, with preclinical data indicating that profound (<20°C) can extend tolerance to ischemia up to 40 minutes without significant neurological deficits in animal models of hypoxic-ischemic . Beyond , DHCA shows potential in complex procedures, where it facilitates surgical access in cases of vascular complications like suprahepatic vena cava . A reported case utilized DHCA to enable safe reconstruction without excessive blood loss, highlighting its role in protecting organs during prolonged ischemia. Similarly, in organ , DHCA-inspired hypothermic techniques are under exploration to extend preservation times for marginal donors, with studies on bloodless solutions demonstrating reduced metabolic demand and cellular injury in isolated organs. Ethical considerations arise with prolonged DHCA durations, particularly regarding potential awareness or implicit during arrest, as recent feasibility studies using electrocortical biomarkers suggest subtle neural activity may persist, raising questions about patient experience and in experimental contexts. Key challenges to broader adoption include scalability in emergency settings and the development of portable cooling devices, as current EPR protocols require specialized equipment that limits field deployment, with ongoing research emphasizing the need for compact, rapid-cooling systems to achieve sub-10°C temperatures without institutional support.

References

  1. https://www.jcvaonline.com/article/S1053-0770(23)00919-9/fulltext
  2. https://www.annalscts.com/article/view/2002/html
  3. https://www.medstarhealth.org/services/deep-hypothermic-circulatory-arrest
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3741856/
  5. https://www.sciencedirect.com/topics/medicine-and-dentistry/deep-hypothermic-circulatory-arrest
  6. https://pubmed.ncbi.nlm.nih.gov/10391334/
  7. https://www.thieme-connect.com/products/ejournals/pdf/10.12945/j.aorta.2014.13-049.pdf
  8. https://thejns.org/view/journals/j-neurosurg/20/7/article-p626.xml
  9. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/nyas.14676
  10. https://www.annalsthoracicsurgery.org/article/S0003-4975%2899%2900814-0/fulltext
  11. https://pubmed.ncbi.nlm.nih.gov/7052001/
  12. https://pubmed.ncbi.nlm.nih.gov/1186283/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4682724/
  14. https://www.jcvaonline.com/article/S1053-0770%2823%2900919-9/fulltext
  15. https://www.mdpi.com/1660-4601/18/13/7061
  16. https://pubmed.ncbi.nlm.nih.gov/18695551/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3298898/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC5030139/
  19. https://www.jtcvs.org/article/S0022-5223(03)00940-1/fulltext
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4203861/
  21. https://pubmed.ncbi.nlm.nih.gov/39096955/
  22. https://www.bjaed.org/article/S1743-1816(17)30341-4/fulltext
  23. https://academic.oup.com/ejcts/article/25/5/691/454874
  24. https://www.uptodate.com/contents/anesthesia-for-aortic-surgery-with-hypothermia-and-elective-circulatory-arrest-in-adult-patients
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC9462422/
  26. https://journals.lww.com/10.2459/JCM.0000000000001152
  27. https://pubmed.ncbi.nlm.nih.gov/21331282/
  28. https://pubmed.ncbi.nlm.nih.gov/29346537/
  29. https://resources.wfsahq.org/wp-content/uploads/373_english.pdf
  30. https://pubmed.ncbi.nlm.nih.gov/11216734/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC5995688/
  32. https://www.annalscts.com/article/view/1687/2372
  33. https://www.jtcvs.org/article/S0022-5223(12)00311-35-8/abstract
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11167524/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7951190/
  36. https://www.annalsthoracicsurgery.org/article/S0003-4975(99)00441-5/pdf
  37. https://academic.oup.com/bjaed/article/10/5/138/274654
  38. https://derangedphysiology.com/main/required-reading/cardiothoracic-surgical-intensive-care/Chapter-8205/deep-hypothermic-circulatory-arrest
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC5462730/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC12318452/
  41. https://www.annalsthoracicsurgery.org/article/S0003-4975(07)00957-5/fulltext
  42. https://pubmed.ncbi.nlm.nih.gov/7856892/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC101145/
  44. https://pubmed.ncbi.nlm.nih.gov/28844545/
  45. https://www.annalscts.com/article/view/16475/html
  46. https://www.jtcvs.org/article/S0022-5223%2803%2900604-4/abstract
  47. https://pubmed.ncbi.nlm.nih.gov/8321002/
  48. https://www.jtcvs.org/article/S0022-5223%2805%2900532-5/fulltext
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6330195/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7378042/
  51. https://www.annalsthoracicsurgery.org/article/S0003-4975(15)00062-4/fulltext
  52. https://pubmed.ncbi.nlm.nih.gov/14562564/
  53. https://pubmed.ncbi.nlm.nih.gov/21847704/
  54. https://www.sciencedirect.com/science/article/pii/S0022522310002291
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5142518/
  56. https://pubmed.ncbi.nlm.nih.gov/19740304/
  57. https://pubmed.ncbi.nlm.nih.gov/26706792/
  58. https://pubmed.ncbi.nlm.nih.gov/33637420/
  59. https://www.ahajournals.org/doi/10.1161/01.cir.0000138387.61103.a0
  60. https://www.jtcvs.org/article/S0022-5223%2816%2931162-X/fulltext
  61. https://academic.oup.com/ejcts/article/50/5/949/2444523
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC12472810/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC5154360/
  64. https://www.nature.com/articles/s41598-020-61428-x
  65. https://www.ahajournals.org/doi/10.1161/JAHA.120.017939
  66. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067022
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4842827/
  68. https://academic.oup.com/ejcts/article/67/2/ezae354/8011475
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC3741852/
  70. https://www.annalscts.com/article/view/2005/html
  71. https://pubmed.ncbi.nlm.nih.gov/10391331/
  72. https://pubmed.ncbi.nlm.nih.gov/26141543/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC11704564/
  74. https://pubmed.ncbi.nlm.nih.gov/25735404/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC12578081/
  76. https://ject.edpsciences.org/articles/ject/abs/2025/03/ject250039/ject250039.html
  77. https://www.jtcvsopen.org/article/S2666-2736%2824%2900242-0/fulltext
  78. https://clinicaltrials.gov/study/NCT01042015
  79. https://pubmed.ncbi.nlm.nih.gov/34859446/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC12541225/
  81. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001164
  82. https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04238-z
  83. https://pubmed.ncbi.nlm.nih.gov/21117254/
  84. https://www.ahajournals.org/doi/10.1161/01.CIR.91.2.431
  85. https://cardiothoracicsurgery.biomedcentral.com/articles/10.1186/s13019-025-03484-w
  86. https://pubmed.ncbi.nlm.nih.gov/28538639/
Add your contribution
Related Hubs
User Avatar
No comments yet.